N/A
Completed N=509
The Rhode Island Prescription and Illicit Drug Study
Source: ClinicalTrials.gov NCT04372238 ↗Enrolled (actual)
509
Serious AEs
5.5%
Results posted
Aug 2025
Primary outcomePrimary: Number of People Identified Has Having One or More Overdose Among RAPIDS Trial Participants — 48; 36 Participants
Summary
This study will test the efficacy of a novel drug-checking intervention to prevent fatal and non-fatal overdose among people who use drugs (PWUD), who are 18-65 years old at the time of enrollment. The investigators will evaluate whether the incorporation of rapid fentanyl testing into a theory-driven overdose education and prevention intervention reduces rates of overdose compared to standard overdose education and naloxone distribution. Results from this study will significantly improve public health efforts to address the fentanyl overdose epidemic and reduce harms associated with exposure to drugs contaminated with fentanyl. This is a full clinical trial, building on the previously approved fentanyl-test-strip pilot study (2016-2017), the results of which have recently been published.(Krieger et al., 2018)
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of People Identified Has Having One or More Overdose Among RAPIDS Trial Participants |
48; 36 | — |
| PRIMARY Accidental Non-fatal Overdose in the Past Month |
5.4; 2.7; 5.6; 4.6; 3.4; 4.0 | — |
| SECONDARY The Number of Fatal Overdose Events |
9; 7 | — |
| SECONDARY Number of Participants With Positive Dry Blood Spot Samples |
34; 35; 86; 79; 125; 128 | — |
Eligibility Criteria
Inclusion Criteria
- Reside in Rhode Island
- Are able to complete interviews in English
- Are able to provide informed consent
- Self-report past 30 day heroin, illicit stimulants, counterfeit prescription pills, or injection drugs
Exclusion Criteria
- Participants who exclusively misuse medications obtained from a physician or diversion from someone else's prescription
Data sourced from ClinicalTrials.gov (NCT04372238). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.